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E-mail address: qin.cheng@defence.gov.au (Q. CheArtemisinin (ART) based combination therapy (ACT) is used as the ﬁrst line treatment of uncomplicated
falciparum malaria in over 100 countries and is the cornerstone of malaria control and elimination pro-
grams in these areas. However, despite the high potency and rapid parasite killing action of ART deriva-
tives there is a high rate of recrudescence associated with ART monotherapy and recrudescence is not
uncommon even when ACT is used. Compounding this problem are reports that some parasites in Cam-
bodia, a known foci of drug resistance, have decreased in vivo sensitivity to ART. This raises serious con-
cerns for the development of ART resistance in the ﬁeld even though no major phenotypic and genotypic
changes have yet been identiﬁed in these parasites. In this article we review available data on the char-
acteristics of ART, its effects on Plasmodium falciparum parasites and present a hypothesis to explain the
high rate of recrudescence associated with this potent class of drugs and the current enigma surrounding
ART resistance.
 2012 Australian Society for Parasitology Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Malaria is caused by the infection of Plasmodium spp. and is
endemic in 106 countries causing an estimated 225 million cases
and 800,000 deaths in 2009 (WHO, 2010b). This high rate of mor-
bidity and mortality is due to the rapid growth and multiplication
of the Plasmodium parasites in host red blood cells. Early and effec-
tive treatment is vital in preventing severe complications and
death, and is a key element of malaria control and elimination
programs.
Several decades ago malaria could be effectively treated using a
variety of antimalarial drugs including chloroquine, pyrimeth-
amine/sulfadoxine (Fansidar), meﬂoquine and atovaquone/progua-
nil (Malarone). Most of these drugs act on the relatively mature
stages of parasites within erythrocytes preventing their further
maturation and multiplication. In the late 1960s P. falciparum
developed resistance to chloroquine and has subsequently devel-
oped resistance to most other drugs rendering them unusable in
many affected areas. Antimalarial resistance resulted in increased
disease burden (Zucker et al., 1996; Trape et al., 1998; Bjorkman,
2002; Tjitra et al., 2008), increased transmission (Price and Nosten,
2001) and epidemics (Warsame et al., 1990). As such, PlasmodiumPublished by Elsevier Ltd.
and Diagnostics, Australian
Qld 4051, Australia. Tel: 61 7
ng).
Open acresistance to anti-malarial drugs has become a major obstacle in
the global ﬁght against malaria.
In 2001, the World Health Organization (WHO) recommended
artemisinin (ART)-based combination therapies (ACTs) as ﬁrst-line
treatment for uncomplicated P. falciparum malaria, and during the
past decade most malaria endemic countries have shifted their na-
tional treatment policies to ACTs (WHO, 2010a). ART and its deriv-
atives are the most potent and rapidly acting antimalarial drugs
(see reviews by Cumming et al. (1997), Gera and Khalil (1997), Li
and Wu (1998), Meshnick (1998, 2002), White (1998b), Balint
(2001), Haynes and Krishna (2004), Olliaro and Taylor (2004), Bray
et al. (2005), Nosten andWhite (2007) and Ding et al. (2010). These
drugs act on all asexual stages of the parasite and are able to re-
duce parasite biomass by up to 10,000-fold per cycle (White,
1997), thus providing rapid relief of symptoms. Importantly, this
class of drug is effective against multi drug resistant parasites.
ACTs also reduce the production of gametocytes and are reported
to have an impact on transmission (Dutta et al., 1989; Kumar
and Zheng, 1990; Price et al., 1996; Targett et al., 2001). For these
reasons ACTs have become the cornerstone of current malaria con-
trol and elimination programs.
Despite the remarkable activity of ART on P. falciparum para-
sites, 3–50% of non-immune patients fail treatment if ART is given
as a mono-therapy (Meshnick and Taylor, 1996). This wide range of
treatment failure rates is mainly due to the duration of treatment,
where higher failure rates were observed after 3 day treatments,
decreasing for 5–7 day treatments. High parasite densities prior
to treatment also contribute to increased treatment failure (Ittaratcess under CC BY-NC-ND license.
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have a short elimination half-life they are not able to eliminate
all parasites during the treatment, resulting in recrudescence
(White, 1997; Kyle et al., 1998; Giao et al., 2001). However,
increasing the treatment duration from 3–5 days to 5–7 days only
reduced (Nguyen et al., 1993), but did not eliminate recrudescence
(McIntosh and Olliaro, 1999; Giao et al., 2001). This result is difﬁ-
cult to explain based on the drugs’ potency and pharmacokinetic/
dynamic properties alone. Interestingly, the parasites collected
from the treatment failures after ART monotherapy are not resis-
tant to ART in vitro (Looareesuwan et al., 1997) and retreatment
is effective (de Vries and Dien, 1996; Ittarat et al., 2003). Fortu-
nately, this high rate of recrudescence could be signiﬁcantly re-
duced by using ART in combination with other antimalarial drugs
such as meﬂoquine, lumefantrine, pyronaridine, and piperaquine,
to form ACTs. To date the reason for the high rate of recrudescence
associated with ART monotherapy and the exact mechanism by
which the combinations reduce recrudescence is uncertain.
One major threat to the efﬁcacy and useful life of ACTs would be
the development of parasite resistance to ART. Recent reports of
parasites in Cambodia with decreased in vivo sensitivity to artesu-
nate (AS), an ART derivative, raises serious concerns for the devel-
opment of ART resistance (Noedl et al., 2008; Dondorp et al., 2009).
The clinical data from western Cambodia showed signiﬁcantly
longer parasite clearance times after AS mono-therapy compared
to cases in north-western Thailand (Dondorp et al., 2009). No ma-
jor changes in parasite phenotype, particularly in vitro IC50 values,
or genotype were detected in the Cambodian parasites. This proﬁle
is different to that of other antimalarial drugs where changes in the
in vitro IC50 values are usually observed in resistant parasites.
While it is clear that the parasites are adapting to ART pressure,
the mechanism responsible is not known. Without a phenotype
or molecular marker it is difﬁcult to monitor and contain the devel-
opment of ART-resistant parasites.
Why are ART monotherapies associated with high rates of
recrudescence? How do ART-combinations reduce recrudescence?
What is the explanation for delayed clearance time observed in
Cambodia? A better understanding of these important questions
may help to protect the efﬁcacy of ART and ACTs. In this article
we review available data and present our interpretations in an ef-
fort to address these questions.
2. The main cause of recrudescence: art-induced dormancy
2.1. The hypothesisBox 1 Deﬁnition of treatment failure (WHO, 2010a).
Treatment failure is defined as an inability to clear malarial
parasitaemia or resolve clinical symptomsdespite administra-
tion of an antimalarialmedicine. Treatment failure is not, how-
ever, always due to drug resistance, and many factors can
contribute, mainly by reducing drug concentrations. These
factors include incorrect dosage, poor patient compliance in
respect of either doseor durationof treatment, poor drugqual-
ity and drug interactions.
In 1996 Kyle and Webster reported that the development of
early ring stage P. falciparum parasites was interrupted following
exposure to AS or dihydroartemisinin (DHA), the metabolite of
several members of the ART family; these parasites survived in
a dormant form for 3–8 days before resuming normal growth
(Kyle and Webster, 1996). This observation led them to hypoth-
esize that some ART-treated parasites enter a state of dormancy,where they are protected from the drug’s lethal effects, but re-
cover at a later date to resume normal growth. The phenomenon
is similar to the post antibiotic effect reported in bacteria (Oden-
holt et al., 1997). Almost at the same time, Bwijo et al. used a
repetitive dosing in vitro model to simulate the in vivo pharma-
cokinetics of ART. Their results indicated that exposure to ART
(3 h pulses once daily) in vitro reduced the number of P. falcipa-
rum asexual parasites to very low levels, but did not completely
eradicate the parasites unless P10 lM ART was used (Bwijo
et al., 1997). The timing of the ‘recrudescent’ growth of these cul-
tures was related to the dose, the frequency and duration of
exposure to the drug. A theoretical mathematical model of AS
treatment was also proposed which included dormancy (Hoshen
et al., 2000). The model output supported the dormancy hypoth-
esis and highlighted the importance of dormancy in selecting the
optimal AS treatment regimen. However more comprehensive
laboratory and ﬁeld evidence were required to conﬁrm this
hypothesis.
2.2. In vitro evidence
To investigate the dormancy hypothesis further in vitro studies
using a single 6 h exposure to 200 ng/ml (7  107 M) DHA,
which is comparable to the serum level of DHA in patients trea-
ted with ART derivatives, were conducted (Teuscher et al.,
2010). It was found that ring stage parasite development was
abruptly arrested following exposure and parasites entered a dor-
mant state lasting up to 20 days (Teuscher et al., 2010). These
dormant parasites had distinct morphological features: the vacu-
ole is not present, the cytoplasm is condensed and tightened to-
wards the nucleus and the nucleus is condensed. Although the
great majority of these parasites die in this state, a proportion
recovered to become growing parasites with a normal morphol-
ogy between 3 and 20 days post-treatment. The overall recovery
rate from dormancy was estimated to be between 0.044% and
1.313%, dependent on parasite line and treatment dose (Teuscher
et al., 2010). Approximately 50% of dormant parasites that recov-
ered resumed growth within 9 days of treatment. Using this
experimental system the authors demonstrated that dormancy
can be readily induced in ring stage P. falciparum. Furthermore,
the authors observed that repeated treatment with DHA for 3
consecutive days, 6 h per day, reduced the recovery rate by 10-
fold highlighting the importance of using a prolonged ART treat-
ment regimen.
2.3. How do ACTs work to reduce recrudescence?
It has been proposed that the main role of the ART component
of ACTs is to rapidly reduce the infecting parasite biomass by as
much as 104-fold every 48 h, while the partner drugs clear the
residual, ART-affected parasites (White, 1999). However, there is
no direct evidence for the exact mechanism by which companion
drugs reduce recrudescence. The companion drugs, which are usu-
ally long-acting, could kill dormant parasites directly or kill para-
sites after they recover from dormancy, or both. To better
understand the mechanism Teuscher et al. treated parasites that
had been exposed to DHA for 6 h with meﬂoquine for 24 h
in vitro. Meﬂoquine was washed off after 24 h to ensure that para-
sites recovering from dormancy were not exposed to the drug.
Magnetic columns were used daily after DHA treatment to remove
any parasites unaffected by DHA in both the DHA alone and DHA
plus meﬂoquine groups. The authors observed a 10-fold reduction
in parasite recovery rate and a delay in recovery compared to DHA
treatment alone (Teuscher et al., 2010). This demonstrated that
meﬂoquine had a direct effect on dormant parasites. Since meﬂo-
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any parasites recovering from dormancy in vivo, thus having a
greater overall effect on parasite recrudescence than that observed
with only one 24 h treatment in vitro.
2.4. In vivo evidence
In contrast to in vitro data there have been no reports to date
that dormant parasites exist in humans following treatment with
ART. This may simply be due to investigators not recognising
these abnormal looking parasites in patients’ blood smears after
treatment. It may also be that human organs such as the spleen
remove severely damaged and dead parasite infected red cells,
and only leave the very small proportion of dormant parasites
circulating at densities below the detection threshold for
microscopy.
To investigate whether dormancy occurs in vivo, LaCrue et al.
developed a synchronous rodent malaria model using P. vinckei
petteri (non-lethal) and P. v. vinckei (lethal) in which the develop-
ment of blood stage parasites is relatively synchronous and para-
sitemias can routinely reach 40% (LaCrue et al., 2011). Infected
mice were treated with AS at different stages of parasite develop-
ment. The results showed that in both the non-lethal and lethal
strains, ring-stage parasites were the least susceptible to treat-
ment, and that 24 h post-treatment dormant parasites similar in
morphology to those seen with P. falciparum in vitro were ob-
served. A transfer experiment was also conducted in which dor-
mant forms from the treated donor mouse were transferred in
varying numbers to different groups of recipient mice. This transfer
experiment identiﬁed a positive correlation between the counted
number of dormant parasites transferred and time to reach 5% par-
asitemia in both intact and asplenic recipient mice (LaCrue et al.,
2011). The recovery rate was estimated to be in the order of 1 in
400 dormant parasites which is comparable to that found
in vitro. Results also showed that dormant parasites required less
time to recover when injected into splenectomised mice compared
to spleen intact mice and that overall survival of asplenic mice was
lower than in the spleen intact group. These data demonstrated a
clear role of the spleen in clearance of parasites following treat-
ment, as well as the possible evasion of spleen pitting of the dor-
mant rings.
2.5. A plausible mechanism for recrudescence
Collectively, these data suggest that dormancy occurs in vitro
and in vivo and is a plausible mechanism for the observed high rate
of recrudescence following ART monotherapy. This parasite pheno-
type means it is imperative that ART is only used in combination
with other antimalarials. Evidence of dormant rings in other ani-
mal models and in patients treated with ART plus evidence of a
relationship between dormant rings and recrudescence will con-
solidate this mechanism. A better understanding of how and what
proportion of dormant parasites survive in vivo in view of ex vivo
evidence that ring stage parasites (Angus et al., 1997) and ART-af-
fected parasites are retained or pitted by spleen (Buffet et al., 2006)
would also help conﬁrm the relationship of dormancy and clinical
recrudescence.
2.6. Why don’t all patients recrudesce?
Based on the published recovery rates, a patient carrying
1  1010 ring-stage parasites (2000 parasites/lL) would have
4  105 parasites that recover following ART treatment. Even if this
rate is reduced by a further 10- or 100-fold by repeated treatment
all patients still have sufﬁcient number of recovered parasites torecrudesce following ART monotherapy. Why then have we not
seen all patients recrudesce?
One possibility is that different parasite isolates have widely
varying recovery rates from dormancy (Teuscher et al., 2012). Since
treatment failure rates are highly sensitive to the dormancy recov-
ery rates (Hoshen et al., 2000; Codd et al., 2011) a population of
parasites with a range of dormancy recovery rates could produce
variable treatment outcome.
Alternatively, host immunity may play a role. Codd et al. con-
ducted a theoretical study combining the in vitro characteristics
of dormant parasites with a P. falciparum infection model (Codd
et al., 2011). The authors were able to demonstrate that estimates
of parasitological and clinical treatment failure rates matched
those measured in ﬁeld trials when the host antibody response
to P. falciparum erythrocyte membrane protein 1 (PfEMP1), a fam-
ily of proteins produced by the antigenically variable var gene, was
included (Codd et al., 2011). In the absence of such an immune re-
sponse all patients were predicted to fail treatment with ART
alone.
2.7. Is dormancy unique to the ART class of compounds?
An important question is whether the dormancy phenomenon
is unique to the ART class of compounds or whether it applies to
other antimalarial drugs. To date there have been no reports
which systematically test different drugs for their effect on induc-
ing dormant parasites. Reports exist on parasite recovery in vitro
following treatment with pyrimethamine, sorbitol and meﬂoquine
(Nakazawa et al., 1995, 2002). Based on similar recovery intervals
observed after different treatments and no change in parasite sus-
ceptibility to drugs after recovery, the authors concluded that
there existed a small proportion of parasites (estimated to be
100 in 107 parasites) capable of surviving the treatment and that
these parasites were not drug resistant. However a fundamental
difference between these results and those using ART is that the
recovery intervals were independent of treatment dose, but corre-
lated with the initial parasite number and length of treatment.
This may suggest a different mechanism to ART-induced
dormancy.
2.8. Is dormancy an innate protection mechanism for all parasites?
Teuscher et al. tested ﬁve P. falciparum strains with different ge-
netic backgrounds and observed that all strains were capable of
becoming dormant following exposure to DHA, although the rate
of recovery differed between strains (Teuscher et al., 2010). This
suggests that ART-induced dormancy is a conserved trait in P. fal-
ciparum parasites. We hypothesize that dormancy is an innate pro-
tection mechanism that parasites use to survive certain types of
stress. It may not be speciﬁc to ART, rather speciﬁc to drugs which
act very early in the erythrocytic cycle, against a particular target,
or drugs causing a speciﬁc type of stress.3. Summary
We suggest that ART-induced dormancy is likely an innate par-
asite response to stress where parasite development is temporar-
ily halted for up to 20 days. After the drug concentration
decreases, a small proportion of dormant parasites recover and re-
sume growth causing recrudescence or treatment failures. The
high efﬁcacy of ACTs is achieved by the companion drug having
a direct impact on the dormant parasites, and in the case of
long-acting companion drugs, by direct suppression of growth of
recovering parasites.
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Only patients who meet the following criteria are classified as
having an artemisinin-resistant infection:
 persistence of parasites 7 days after treatment or recru-
descence within 28 days after the start of treatment,
 adequate plasma concentration of dihydroartemisinin,
 prolonged time to parasite clearance and
 reduced in vitro susceptibility to dihydroartemisinin.
Current working definition of ART resistance (WHO,
2010a)
 an increase in parasite clearance time, as evidenced by
10% of cases with parasites detectable on day 3 after treat-
ment with an ACT (suspected resistance); or
 treatment failure after treatment with an oral artemisinin-
based monotherapy with adequate antimalarial blood
concentration, as evidenced by the persistence of para-
sites for 7 days, or the presence of parasites at day 3 and
recrudescence within 28/42 days (confirmed resistance).The emergence of ART resistance has always been a serious con-
cern since the worldwide introduction of ACTs in 2001. It is consid-
ered almost inevitable that resistance will develop as history
shows parasites have developed resistance to all other widely used
antimalarial drugs. It has long been proposed that combination
therapy should delay the development of resistance (Peters,
1990; White, 1998a) and this principle has been applied to ACTs.
However, reports of parasites in Cambodia with decreased in vivo
sensitivity to ART (Noedl et al., 2008; Dondorp et al., 2009) have
conﬁrmed the emergence of resistance in the ﬁeld although the
clinical efﬁcacy of ACT has not been compromised at this stage. It
is uncertain howmuch unauthorized use of suboptimal ART mono-
therapy may have contributed to this situation.
4.1. Field observations
ART treatment has been extensively used in China for more than
20 years and until now there has been no documentation of ART
resistance in that country. In 2003 Yang et al. reported a three-fold
reduction in the in vitro susceptibility of P. falciparum to AS be-
tween 1988 and 1999 in Yunnan, Southwest China (Yang et al.,
2003).
The ﬁrst clear, well documented evidence of ART resistance was
provided by the results of two separate efﬁcacy trials conducted in
Western Cambodia (Noedl et al., 2008; Dondorp et al., 2009). The
ﬁrst trial was conducted in Battambang Province using AS mono-
therapy; four out of 60 patients recrudesced and two patients
had prolonged parasite-clearance times. Parasite isolates from
these two patients had a four-fold increase in ex vivo IC50 values
compared to those of cured patients, and a 10-fold increase com-
pared to a reference clone (Noedl et al., 2008). The second trial
was conducted in Cambodia and Thailand using AS monotherapy
and AS plus meﬂoquine (Dondorp et al., 2009). The results revealed
a signiﬁcant delay in parasite clearance time in Cambodian pa-
tients, suggesting the Cambodian P. falciparum isolates had re-
duced susceptibility to AS. However, few other phenotypic
changes were identiﬁed. Unlike the ﬁrst trial the Thai and Cambo-
dian isolates collected in this trial showed no signiﬁcant differ-
ences in their susceptibility (IC50 values) to either DHA or ASwhen measured using conventional in vitro drug susceptibility
tests (Dondorp et al., 2009). No correlation between the delayed
parasite clearance and tested putative molecular markers such as
pfmdr1, pfATPase6, pfcrt, the 6 kb mitochondrial genome and
pfubp-1 were found. Although the resistance was identiﬁed to be
heritable (Anderson et al., 2010), the molecular mechanism of
resistance is currently unknown. Results from Genome-wide stud-
ies on these isolates are beginning to be published (Mok et al.,
2011), and may help identify changes associated with the delayed
clearance phenotype.
Reduced susceptibility of ring-stage parasites to ART has been
proposed as an explanation for the prolonged clearance times ob-
served in Cambodia (Dondorp et al., 2009; Saralamba et al.,
2010). Mathematical modelling of this hypothesis reproduced the
observed parasite clearance for each patient in the trial (Saralamba
et al., 2010). This hypothesis also explains why conventional
in vitro susceptibility tests that assess the drug effect on the mat-
uration of parasites from ring to schizont stage (Dondorp et al.,
2009) did not detect any difference in IC50 value between parasites
with normal and prolonged clearance time; the change in suscep-
tibility caused by ring stage resistance alone would be expected to
be smaller than that caused by resistance of all stages, and the con-
ventional in vitro susceptibility assay is not sensitive enough to
measure the small difference.
ART-induced dormancy also has been proposed as the reason
conventional drug susceptibility assays do not detect ART resis-
tance in vitro (Tucker et al., 2012). In conventional assays the par-
asites are exposed to drug for 24–48 h prior to the addition of a
growth indicator (e.g., 3H-hypoxanthine); this time is more than
adequate for the ring stage parasites to enter the dormant state.
Therefore Tucker et al. hypothesized that by adding 3H-hypoxan-
thine at time zero (i.e., the same time as drug) any differences in
growth of resistant rings would be observed (Tucker et al., 2012).
Data with in vitro derived ART-resistant lines of P. falciparum in
the modiﬁed assay conﬁrmed reduced susceptibility of ART-resis-
tant W2 and D6 lines to artelinic acid (AL), ART, and DHA (Tucker
et al., 2012) .
Two urgent tasks face the malaria community: (1) contain the
ART-resistant parasites at the foci because their spread could lead
to a widespread loss of ACT efﬁcacy and a resurgence of malaria
morbidity and death; (2) monitor the emergence of ART resistance
in other areas. In order to achieve these important public health
goals we need to identify phenotype and genotype changes associ-
ated with these resistant parasites and understand the biological
and molecular mechanisms of resistance.
4.2. ART resistance in the laboratory
Laboratory selected resistant parasites can provide critical in-
sight about phenotypic and genotypic changes associated with
resistance. For this purpose, several laboratories have developed
ART-tolerance/resistance in culture adapted parasite lines (Insel-
burg, 1985; Jiang, 1992; Yang et al., 1999; Chavchich et al., 2010;
Witkowski et al., 2010; Beez et al., 2011; Tucker et al., 2012) and
in animal models (Chawira et al., 1986; Afonso et al., 2006; Hunt
et al., 2007). These lines have been used to investigate the biology
and mechanisms of resistance, however many of the earlier resis-
tant lines have proved to be unstable (Jiang, 1992) or only achieved
relatively low levels of resistance as measured by in vitro suscepti-
bility tests (Jiang, 1992; Yang et al., 1999), while others are no
longer available for study (Inselburg, 1985).
A recent study reported the selection of an ART tolerant-P. falci-
parum line that can tolerate concentrations 7000-fold higher than
the initial IC50 for 48–96 h and recover after the drug pressure
was withdrawn (Witkowski et al., 2010). Interestingly only ring
stage parasites were observed in cultures that were under drug
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under continuous drug pressure. The major phenotypic change in
the adapted line was an early recovery from dormancy compared
to the parental line (Witkowski et al., 2010). No changes in
in vitro IC50 value were detected in this line and no association with
candidate drug resistant markers was identiﬁed (Witkowski et al.,
2010). Transcriptome analysis only detected signiﬁcant changes in
the expression of six genes which all encode for exported protein
families with the majority involved in antigenic variation. Since
the adapted line can tolerate short term high drug concentrations
and recover rapidly, we suggest that this line has only changed
its dormancy proﬁle, rather than developing full resistance where-
by parasites can mature and multiply under drug pressure.
Chavchich et al. also selected in vitro parasite lines that are resis-
tant to an ART derivative, AL from three different parental lines
(Chavchich et al., 2010). The IC50 values for these lines showed
modest increases of 2–5-fold after the initial selection and up to
12-fold after renewed drug selection (Chen et al., 2010). In contrast
to the drug tolerant line reported by Witkowski et al. (2010), these
lines were able to grow for at least 20 days under continued AL drug
pressure at concentrations to which they had become adapted, that
is 17-fold above the IC50 value of parental parasites. The observed
changes in IC50 valueswere accompanied by increases in copy num-
ber, mRNA expression, and protein expression of the pfmdr1 gene
for 2 of the 3 resistant lines (Chavchich et al., 2010). The IC50 values
were partially reversed when de-ampliﬁcation of the pfmdr1-con-
taining amplicon occurred after culture in the absence of drug-pres-
sure for 3 months (Chen et al., 2010).
A more recent study reported heterogeneity among parents and
progeny of the HB3  Dd2 cross in their in vitro susceptibility to
ART (Beez et al., 2011). Polymorphisms in the pfmdr1 gene, plus
loci on chromosomes 12 and 13 were identiﬁed as contributing
to ART susceptibility. Further selection of a stable ART-resistant
P. falciparum from a F1 progeny of a genetic cross resulted in a
moderate 2- to 4- fold increase in IC50 level. However no additional
genetic changes were identiﬁed.
4.3. Phenotypes of ART-resistant laboratory lines
Recent laboratory studies (Teuscher et al., 2012) investigated
the phenotype of the AL resistant lines reported earlier (Chavchich
et al., 2010). Similarly these lines were exposed to higher levels of
AL drug pressure as well as to ART and DHA that induced cross-
resistance to ART derivatives (Tucker et al., 2012). Through de-
tailed examination of the dormancy proﬁle and growth character-
istics of the resistant lines authors of these studies identiﬁed three
changes in these parasites:
1) Decreased sensitivity in the ring stage to the induction of
dormancy. A signiﬁcantly reduced percentage of ring-stage
parasites became dormant following a single exposure to
AL, compared to the parental line. For instance, exposing
parental lines to 20 ng/mL AL for 6 h was sufﬁcient to cause
over 90% dormant rings, while for resistant parasite lines,
only concentrations of 640 ng/mL AL, which is at least 8-fold
higher than concentrations to which they were adapted,
resulted in 80% dormant rings (Teuscher et al., 2012). This
phenotype supports a hypothesis that dormancy is a
response to stress that is triggered when parasites cannot
tolerate drug pressure. It is a reﬂection of parasite resistance
to AL.
2) Decreased sensitivity in mature stage parasites. Healthy
mature stage parasites were seen in cultures >24 h of drug
pressure, suggesting that some parasites can grow and mul-
tiply under drug concentrations which kill the parental
parasites.3) When dormancy is induced (using a higher drug concentra-
tion) the resistant parasites recover faster leading to earlier
recrudescence.
These 3 phenotypic changes provide a proﬁle for ART resistance
that has not previously been reported in laboratories or in the ﬁeld.
4.4. A hypothesis for the development of ART resistance
Combining clinical observations from the ﬁeld with in vitro, ani-
mal and theoretical studies, we hypothesise that resistance to ART
develops as a two-step process which is linked to the dormancy
phenomenon. These stages are described below and illustrated in
Fig. 1.
In the absence of resistance the wild type parasites are suscep-
tible to ART derivatives. When exposed to ART, sensitive parasites
activate a stress response which results in close to 100% ring stage
parasites becoming dormant. Conversely, mature stage parasites
are killed by the drug. A very small proportion of dormant parasites
recover at a rate dictated by the level of stress, that is, the concen-
tration of drug. In the case of ART monotherapy, dormant parasites
recover to cause treatment failure in some patients, dependent on
the host immune response. When ART is used as part of ACT, the
companion drug may have a direct effect by reducing the number
of dormant parasites which recover, as well as killing parasites
after they recover. This is the situation which applies to the major-
ity of malaria endemic areas.
The ﬁrst step toward the development of ART resistance in-
volves changes in the dormancy proﬁle. After repeated exposure
to ART some ring stage parasites adapt such that ART exposure in-
duces a lower level of stress, causing a signiﬁcantly smaller propor-
tion of ring-stage parasites to become dormant. These tolerant ring
stages can mature to trophozoites under drug pressure, but per-
haps at a reduced speed. This slower parasite maturation results
in parasites remaining in the circulation for 48–72 h causing a
lengthening of parasite clearance times and a shift of the clearance
curve. As the parasites reach mature stage they are killed by the
drug as these stages are still sensitive to ART. Conventional
in vitro susceptibility testing will not detect signiﬁcant changes
in parasite IC50 values during this stage since mature stage para-
sites are equally sensitive to ART. The Cambodian ﬁeld isolates
(Dondorp et al., 2009) and the resistant line adapted by Witkowski
et al (Witkowski et al., 2010) would ﬁt into this stage of resistance
development.
As resistance further develops to the second stage, not only ring
stage but also mature stage parasites become less susceptible to
ART. At this stage drug pressure at therapeutic levels is no longer
sufﬁcient to trigger the stress response of dormancy in the major-
ity of ring stage parasites and mature parasites are able to grow
and multiply under drug pressure. These parasites will cause treat-
ment failures following ART monotherapy and ACT, depending on
the efﬁcacy of the companion drug. These parasites will show an
increase in IC50 value when measured by conventional in vitro sus-
ceptibility test. When higher drug doses are used, the stress re-
sponse can again be triggered and the parasites will use the
dormancy mechanism to survive the high drug pressure. Fortu-
nately this situation has not been seen in the ﬁeld but the AL resis-
tant parasites developed in vitro (Teuscher et al., 2012) ﬁt this stage
of resistance.
The molecular changes which are responsible for stage 1 and 2
resistance are not known. Indeed the pathways associated with
dormancy itself are still to be elucidated. It is possible that the
same molecular changes are responsible for both stages of resis-
tance, although more likely that a different mechanism exists for
ART tolerance in ring stage parasites and survival of mature stages.
We hypothesise that at stage 1, ring stage parasites may develop a
Fig. 1. Schematic illustration of the developmental steps of ART resistance.
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This tolerance reduces the level of stress experienced by parasites
during ART exposure, which is reﬂected by changes in dormancy
proﬁle, namely fewer parasites becoming dormant. One possible
mechanism to achieve this may be through cell cycle regulation
mechanisms. Resistance of mature parasites, as seen in the stage
2, may involve signiﬁcant or more alterations (mutations) of drug
targets or alterations in transporters. Laboratory evidence suggests
that ampliﬁcation of pfmdr1 (Chavchich et al., 2010; Chen et al.,
2010; Tucker et al., 2012) may be associated with survival of ma-
ture stage parasites, although it is unlikely to be solely responsible.
Other candidate genes such as pfATPase 6 (Uhlemann et al., 2005),
pftctp (Bhisutthibhan et al., 1998) and pfubp-1(Hunt et al., 2007)
may also be involved even though they are not implicated in ﬁeld
isolates at this early stage of resistance development.
Currently, the best marker for ART resistance is the reduced par-
asite clearance rate observed as part of therapeutic efﬁcacy trials.
These trials are expensive and time consuming; an in vitro test
would greatly improve resistance monitoring. Tolerability of ring
stage parasites to ART could be used as a marker for a new
in vitro susceptibility test where the output is not the percentage
of parasites that reach schizonts, rather the percentage of rings that
survive to trophozoites, or the percentage of rings becoming dor-
mant following drug exposure. If the ART resistance is stopped at
stage 1, we may not detect signiﬁcant IC50 changes in ﬁeld isolates.
A better understanding of the processes underlying the devel-
opment of resistance, and mechanisms of resistance, will greatly
assist the effort to monitor, contain and eliminate ART resistant
parasites, and most importantly to prevent detrimental public
health consequences that may be caused by the spread of ART
resistance.
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